Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02258347
Other study ID # HIFU/REG/NT
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 2014
Est. completion date October 13, 2015

Study information

Verified date May 2018
Source Theraclion
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Use of a high intensity focused ultrasound (HIFU) in patients with non-malignant thyroid nodules.


Recruitment information / eligibility

Status Completed
Enrollment 4
Est. completion date October 13, 2015
Est. primary completion date October 13, 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female patient 18 years or older.

- Patient presenting with at least one thyroid nodule with no signs of malignancy:

1. Non suspect clinically and at ultrasonography imaging

2. Benign cytological diagnosis at fine-needle aspiration biopsy (FNAB) from the last 6 months

3. Normal serum calcitonin

4. No history of neck irradiation

- Normal thyroid-stimulating hormone (TSH).

- Targeted nodule accessible and eligible to HIFU

- Absence of abnormal vocal cord mobility at laryngoscopy.

- Nodule diameter = 10mm measured by ultrasound.

- Nodule volume inferior to 10 cc

- Composition of the targeted nodule(s) : no more than 30% cystic

Exclusion Criteria:

- Head and/or neck disease that prevents hyperextension of neck.

- Known history of thyroid cancer or other neoplasias in the neck region.

- History of neck irradiation.

- Macrocalcification inducing a shadow in the thyroid significant enough to preclude the HIFU treatment

- Posterior position of the nodule if the thickness of the nodule is <15mm

- Pregnant or lactating woman

- Any contraindication to the assigned analgesia/anaesthesia.

Study Design


Intervention

Device:
Echopulse


Locations

Country Name City State
Italy Istituto in tecnologie avanzate e modelli assistenziali in oncologia Reggio Emilia

Sponsors (1)

Lead Sponsor Collaborator
Theraclion

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of thyroid nodule's volume changes following HIFU therapy assessed by ultrasonography (US) Month 6 and Month 12
Primary Evaluation of thyroid nodule's structure changes following HIFU therapy assessed by ultrasonography (US) Month 6 and Month 12
Primary Evaluation of thyroid nodule's vascularisation changes following HIFU therapy assessed by ultrasonography (US) Month 6 and Month 12
Secondary Number of subjects with adverse events as a measure of safety and tolerability Day 1, Month 1, Month 3, Month 6 and Month 12